NCT04426669: An ongoing trial by Intima Bioscience, Inc.
This trial is ongoing. It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04426669 |
|---|---|
| Title | A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 15, 2020 |
| Completion date | Jan. 31, 2026 |
| Required reporting date | Jan. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |